α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome
- PMID: 22471591
- DOI: 10.1111/j.1464-410X.2012.11088.x
α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome
Abstract
Study Type - Therapy (systematic review) Level of Evidence 1a. What's known on the subject? and What does the study add? Individual clinical trials evaluating antibiotics, anti-inflammatories and α-blockers for the treatment of chronic prostatitis/chronic pelvic pain syndrome have shown only modest or even no benefits for patients compared with placebo, yet we continue to use these agents in selected patients with some success in clinical practice. This network meta-analysis of current evidence from all available randomized placebo-controlled trials with similar inclusion criteria and outcome measures shows that these '3-As' of chronic prostatitis/chronic pelvic pain syndrome treatment (antibiotics, anti-inflammatories and α-blockers) do offer benefits to some patients, particularly if we use them strategically in selected individuals.
Objectives: To provide an updated network meta-analysis mapping α-blockers, antibiotics and anti-inflammatories (the 3-As) in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). • To use the results of this meta-analysis to comment on the role of the 3-As in clinical practice.
Patients and methods: We updated a previous review including only randomized controlled studies employing the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) as one of the outcomes to compare treatment effects in CP/CPPS patients. • A longitudinal mixed regression model (network meta-analysis) was applied to indirectly assess multiple treatment comparisons (i.e. α-blockers, antibiotics, anti-inflammatory/immune modulation therapies, α-blockers plus antibiotics, and placebo).
Results: Nineteen studies (1669 subjects) were eligible for analysis. • α-blockers, antibiotics and anti-inflammatory/immune modulation therapies were associated with significant improvement in symptoms when compared with placebo, with mean differences of total CPSI of -10.8 (95% CI -13.2 to -8.3; P < 0.001), -9.7 (95% CI -14.2 to -5.3; P < 0.001) and -1.7 (95% CI -3.2 to -0.2; P= 0.032) respectively, while α-blockers plus antibiotics resulted in the greatest CPSI difference (-13.6, 95% CI -16.7 to -10.6; P < 0.001). • With respect to responder analysis compared with placebo, anti-inflammatories showed the greatest response rates (risk ratio 1.7, 95% CI 1.4-2.1; P < 0.001) followed by α-blockers (risk ratio 1.4, 95% CI 1.1-1.8; P= 0.013) and antibiotics (risk ratio 1.2, 95% CI 0.7-1.9; P= 0.527).
Conclusions: α-blockers, antibiotics and/or anti-inflammatory/immune modulation therapy appear to be beneficial for some patients with CP/CPPS. • The magnitude of effect and the disconnect between mean CPSI decrease and response rates compared with placebo suggest that directed multimodal therapy, rather than mono-therapy, with these agents should be considered for optimal management of CP/CPPS.
© 2012 BJU INTERNATIONAL.
Comment in
-
Re: α-Blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome.J Urol. 2013 Jun;189(6):2130-1. doi: 10.1016/j.juro.2013.02.3226. Epub 2013 Mar 6. J Urol. 2013. PMID: 23663605 No abstract available.
Similar articles
-
Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis.JAMA. 2011 Jan 5;305(1):78-86. doi: 10.1001/jama.2010.1913. JAMA. 2011. PMID: 21205969 Review.
-
Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome.Eur Urol. 2016 Feb;69(2):286-97. doi: 10.1016/j.eururo.2015.08.061. Epub 2015 Sep 26. Eur Urol. 2016. PMID: 26411805 Review.
-
Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome.Cochrane Database Syst Rev. 2019 Oct 6;10(10):CD012552. doi: 10.1002/14651858.CD012552.pub2. Cochrane Database Syst Rev. 2019. PMID: 31587256 Free PMC article. Review.
-
Network Meta-Analysis of the Efficacy of Acupuncture, Alpha-blockers and Antibiotics on Chronic Prostatitis/Chronic Pelvic Pain Syndrome.Sci Rep. 2016 Oct 19;6:35737. doi: 10.1038/srep35737. Sci Rep. 2016. PMID: 27759111 Free PMC article.
-
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.Urology. 2003 Sep;62(3):425-9. doi: 10.1016/s0090-4295(03)00466-7. Urology. 2003. PMID: 12946740 Clinical Trial.
Cited by
-
The methodological quality assessment of systematic reviews/meta-analyses of chronic prostatitis/chronic pelvic pain syndrome using AMSTAR2.BMC Med Res Methodol. 2023 Nov 27;23(1):281. doi: 10.1186/s12874-023-02095-0. BMC Med Res Methodol. 2023. PMID: 38012566 Free PMC article.
-
The efficacy and safety of low-intensity extracorporeal shock wave treatment combined with or without medications in Chronic prostatitis/chronic pelvic pain syndrome: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2023 Sep;26(3):483-494. doi: 10.1038/s41391-022-00571-0. Epub 2022 Jul 7. Prostate Cancer Prostatic Dis. 2023. PMID: 35798855 Review.
-
Oral pharmacological treatments for chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis of randomised controlled trials.EClinicalMedicine. 2022 May 20;48:101457. doi: 10.1016/j.eclinm.2022.101457. eCollection 2022 Jun. EClinicalMedicine. 2022. PMID: 35706494 Free PMC article.
-
Morphological study of chronic prostatitis-chronic pelvic pain syndrome (CP/CPPS) normal modeling dose of T2 peptide in mice.Int Urol Nephrol. 2022 Jun;54(6):1199-1206. doi: 10.1007/s11255-022-03185-6. Epub 2022 Apr 19. Int Urol Nephrol. 2022. Retraction in: Int Urol Nephrol. 2023 Nov;55(11):2815. doi: 10.1007/s11255-023-03788-7. PMID: 35438412 Retracted.
-
Dihydroartemisinin Promoted Bone Marrow Mesenchymal Stem Cell Homing and Suppressed Inflammation and Oxidative Stress against Prostate Injury in Chronic Bacterial Prostatitis Mice Model.Evid Based Complement Alternat Med. 2021 Dec 15;2021:1829736. doi: 10.1155/2021/1829736. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34956376 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous